Probiotika sind nicht gleich Probiotika – warum der genaue Stamm entscheidend ist

Not all probiotics are the same – why the specific strain is crucial

When it comes to bacterial cultures in dietary supplements, it pays to take a close look at the label. After all, genus, species, and strain are not the same thing.

A simple example:

Bacillus = genus
subtilis = species
HU58™ = specific strain

This is scientifically relevant. Results from an investigation using a specific strain cannot automatically be applied to other strains of the same species.

The number of microorganisms contained – often indicated as CFU (colony-forming units) – is also not a quality feature in itself. A high number only indicates the quantity, not how well that particular strain has been scientifically studied.

Two current human studies with HU58™

There are now two randomized, double-blind, and placebo-controlled human studies available for Bacillus subtilis HU58™. What is particularly interesting about these is their strain specificity.

Study 1: HU58™ as a single strain

In 2025, a study was published involving 68 children aged 1 to 12 years who already had antibiotic-associated diarrhea.

Over seven days, the children received either a placebo or 2 billion CFU of Bacillus subtilis HU58™ daily.

On the third day of the study, 93.5% of the children in the HU58 group showed normal stool consistency, compared to 22.6% in the placebo group. By day seven, however, almost all children in both groups had normal stool consistency again.

Thus, the investigation shows a clear difference at an early measurement point. At the same time, the context is important: the study examined children with a clearly defined clinical condition. No general effect on healthy individuals or other digestive issues can be derived from this.

Study 2: HU58™ together with SC208

In 2026, another randomized, double-blind, and placebo-controlled pilot study was published involving 61 adults with diarrhea-predominant irritable bowel syndrome.

Over four weeks, a combination of

Bacillus subtilis HU58™ + Heyndrickxia faecalis SC208

was compared with a placebo.

For several endpoints studied, including abdominal pain and stool consistency, the groups showed statistically significant differences.

However, a crucial limitation applies here: HU58™ was used in conjunction with a second strain. Therefore, the results cannot be attributed to HU58™ alone.

What can be concluded from this?

Above all, one thing: when it comes to bacterial cultures, scientific evidence should always be considered strain-specific.

The two studies did indeed examine HU58™. However, they differ significantly in terms of population, combination, study duration, and research question.

This is precisely why the statement "Bacillus subtilis is scientifically studied" is too nonspecific.

Scientific classification

The described results reflect the findings of the respective scientific publications. They do not constitute a claim regarding the prevention, treatment, or cure of a disease through a dietary supplement.